India’s pharmaceutical industry is expected to fall significantly short of its previously established sales target for 2030 as trade uncertainty and disruptions to international shipping weigh on the sector.
The Pharmaceuticals Export Promotion Council of India now expects the country’s pharmaceutical industry to reach approximately $80 billion to $90 billion in sales by 2030. That is substantially below the industry’s previous target of $130 billion.
India is one of the world’s major pharmaceutical manufacturing and exporting hubs, particularly in generic medicines. Its pharmaceutical industry supplies medicines to markets around the world, making international trade conditions particularly important to manufacturers.
According to the trade body’s assessment, uncertainty surrounding U.S. tariffs and disruptions affecting shipping routes in the Middle East are creating additional pressure on pharmaceutical exporters. The effects extend beyond individual companies because pharmaceutical manufacturing depends on complex international supply chains for ingredients, packaging, transportation and finished products.
The revised outlook highlights the challenges facing one of the world’s most important sources of affordable medicines. It also demonstrates how geopolitical developments and global trade policies can affect pharmaceutical production and access far beyond the countries where those policies originate.
